Table 1.

Description of the population (included and adjusted) and univariate analysis of association with IgG anti-SARS-CoV-2 seropositivity (p-value and odds ratio (OR)).

Items		Included Population						Weighted Population
		All (n)	EUROIMMUN IgG SARS-CoV-2 Positives			OR [95% CI]	p-Value	All (n)	Weighted Seroprevalences			OR [95%CI]	p-Value
			n Positive	SARS-CoV-2 IgG+ (%)	[95% CI]				n Positives	Seroprevalence (%)	[95% CI]
Overall		1973	104	5.27	[4.33–6.35]			1973	107.66	5.46	[4.37–7.00]
Sex	Women	1187	66	5.56	[4.33–7.02]	0.86 [0.57–1.29]	0.48	1017.35	58.41	5.74	[4.31–7.17]	0.89 [0.56–1.42]	0.63
	Men	786	38	4.83	[3.44–6.58]			955.48	49.25	5.15	[3.75–6.56]
Age (years)	0–9	40	1	2.50	[0.063–13.16]	0.73 [0.04–3.99]	< 0.0001 *	193.05	6.22	3.22	[0.73–5.71]	1.03 [0.13–8.36]	0.97
	10–19	153	15	9.80	[5.59–15.65]	3.11 [1.38–7.32] *		199.79	20.85	10.44	[6.20–14.68]	3.62 [1.54–8.53] *	0.0033 *
	20–29	197	7	3.55	[1.44–7.18]	1.05 [0.38–2.79]		191.59	6.72	3.51	[0.90–6.10]	1.13 [0.40–3.19]	0.82
	30–39	235	20	8.51	[5.27–12.84]	2.66 [1.25–6.04] *		249.66	22.16	8.88	[5.35–12.40]	3.01 [1.35–6.69] *	0.0069 *
	40–49	269	28	10.41	[7.03–14.69]	3.32 [1.63–7.32] *		258.47	27.08	10.48	[6.74–14.21]	3.62 [1.71–7.68] *	0.00079 *
	50–59	296	10	3.38	[1.63–6.12]	reference		274.30	8.58	3.13	[1.07–5.19]	reference
	60–69	273	4	1.47	[0.40–3.71]	0.43 [0.12–1.29]		257.60	3.78	1.47	[0.00–2.94]	0.46 [0.14–1.50]	0.20
	70–79	237	9	3.80	[1.75–7.09]	1.13 [0.44–2.85]		209.46	7.92	3.78	[1.20–6.36]	1.21 [0.48–3.05]	0.68
	80–89	184	5	2.72	[0.89–6.23]	0.80 [0.25–2.29]		111.32	2.80	2.52	[0.00–5.42]	0.79 [0.26–2.36]	0.68
	90 and older	89	5	5.62	[1.85–12.62]	1.70 [0.52–4.93]		27.59	1.55	5.62	[0.00–14.21]	1.80 [0.59–5.49]	0.30

SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; IgG: Immunoglobulin G; OR: Odd Ratio; CI: Confidential Interval; * the asterisk means that the figures concerned are significant (p-value < 0.05) and OR not including 1.